Lineage Cell Therapeutics, Inc 10-Q for FY2026 Q3
Lineage Cell Therapeutics, Inc. (LCTX)
10-Q
2026-11-12
For: 2026-09-30
View Original
Added on
November 13, 2026
About this 10-Q
Lineage Cell Therapeutics, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Lineage acquired NeuroAirmid on November 12, 2026, adding the HUNT1 cell therapy for Huntington’s Disease. It paid $2.4 million in cash and issued 2.2 million common shares, with up to $48.0 million contingent on clinical development and regulatory milestones. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $1.43M
- down 61.0% from $3.68M a year earlier
- Net income
- $4.23M
- compared with a net loss of $29.78M a year earlier
- Diluted EPS
- -$0.03
- compared with -$0.13 a year earlier